Basis: Four-quarter operating cash flow / FMP quote market capitalization × 100. Source: stored company filings and market data; unavailable inputs remain N/A.
The operating cash flow yield is N/A as of 2026-10-06T16:37:58.282Z.
Calculation as of: 2026-10-06T16:37:58.282Z.
Quote observation: 2026-10-06T16:35:16.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 985de651f734d9a38a22cd49a3876f31e599b575395053e6524d1a54e91db9a8
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
OPERATING CASH FLOW YIELD
N/A
Lyell Immunopharma, Inc.
Market Cap
$218.59M
Operating Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$218.36M
Operating Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$216.72M
Operating Cash Flow Yield
N/A
TTM Avg
41.63%
3Y Avg
41.53%
5Y Avg
35.39%
Market Cap
$221.57M
Operating Cash Flow Yield
N/A
TTM Avg
14.77%
3Y Avg
14.64%
5Y Avg
14.64%
Market Cap
$214.64M
Operating Cash Flow Yield
2.77%
TTM Avg
2.54%
3Y Avg
2.69%
5Y Avg
2.62%
Market Cap
$213.50M
Operating Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$209.50M
Operating Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$208.02M
Operating Cash Flow Yield
N/A
TTM Avg
10.33%
3Y Avg
10.33%
5Y Avg
10.33%
| NAME | MARKET CAP | OPERATING CASH FLOW YIELD | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Lyell Immunopharma, Inc. (LYEL) | $218.59M | N/A | N/A | N/A | N/A |
| Anbio Biotechnology Class A Ordinary Shares (NNNN)vs › | $218.36M | N/A | N/A | N/A | N/A |
| Alector, Inc. (ALEC)vs › | $216.72M | N/A | 41.63% | 41.53% | 35.39% |
| Keros Therapeutics, Inc. (KROS)vs › | $221.57M | N/A | 14.77% | 14.64% | 14.64% |
| Niagen Bioscience Inc (NAGE)vs › | $214.64M | 2.77% | 2.54% | 2.69% | 2.62% |
| Prelude Therapeutics Incorporated (PRLD)vs › | $213.50M | N/A | N/A | N/A | N/A |
| Compugen Ltd. (CGEN)vs › | $211.33M | N/A | N/A | N/A | N/A |
| Sionna Therapeutics, Inc. (SION)vs › | $209.50M | N/A | N/A | N/A | N/A |
| Cartesian Therapeutics, Inc. (RNAC)vs › | $208.02M | N/A | 10.33% | 10.33% | 10.33% |
| Profound Medical Corp. (PROF)vs › | $229.65M | N/A | N/A | N/A | N/A |
OCF Yield = TTM Operating Cash Flow / Market Cap
Operating cash flow yield is the inverse of P/OCF, expressing trailing operating cash flow as a percentage of price. It sits between earnings yield (before non-cash accrual effects) and FCF yield (before capital expenditure).
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
